Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • IAPT

    - PMLiVE

    UK and US agree on landmark pharma pricing tariff deal

    US tariffs on UK-produced pharmaceuticals will remain at zero for three years

    - PMLiVE

    ViiV Healthcare receives NICE recommendation for HIV prevention therapy

    The treatment is the first and only long-acting HIV prevention option available on the NHS in England and Wales

    - PMLiVE

    La Roche-Posay launches global campaign to spotlight the visible and invisible impact of scars

    ‘Scars of Life’ aims to raise awareness of the psychological burden associated with skin conditions and scarring

    - PMLiVE

    From Burnout to Balance: New Campaign Focuses on the ‘Matters’ that are Really Affecting Our ‘Minds’ in Health Communications

    Launched on World Mental Health Day, Minds on Matters aims to highlight mental wellbeing challenges while showcasing practical solutions and positive change

    Fox&Cat

    - PMLiVE

    Pfizer’s Lorviqua recommended by NICE for lung cancer

    Lung cancer is the leading cause of cancer-related deaths worldwide

    - PMLiVE

    New National Commission launched to strengthen AI regulation

    The Commission will unite healthcare leaders, regulators and technology experts to shape future AI governance

    ECA webinar image

    ISPOR hosts expert webinar exploring the value of ECAs for regulatory and HTA evidence needs

    On Tuesday, October 7th, you are invited to join a Genesis Research Group-led webinar exploring the value of External Control Arm (ECA) studies. Gaining traction as part of evidence generation...

    Genesis Research Group

    - PMLiVE

    NHS programme to give head and neck cancer patients fast-track access to mRNA vaccine

    More than 11,000 people are diagnosed with head and neck cancers every year in England

    - PMLiVE

    NICE recommends ALK’s immunotherapy to target underlying cause of hay fever

    An estimated 26,800 people in England with moderate-to-severe cases could benefit from Itulazax

    - PMLiVE

    NICE recommends BeOne’s Brukinsa to treat mantle cell lymphoma on NHS

    Approximately 600 people are affected by the form of non-Hodgkin lymphoma every year in the UK

    - PMLiVE

    Novartis’ Kisqali recommended by NICE to treat broad early breast cancer population

    The drug was previously available only for patients whose cancer had spread to nearby lymph nodes

    - PMLiVE

    Vertex’s triple combination cystic fibrosis therapy Alyftrek recommended by NICE

    The rare inherited disease affects approximately 11,000 people in the UK

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links